Silverback Therapeutics Inc is a biotechnology business based in the US. Silverback Therapeutics shares (SBTX) are listed on the NASDAQ and all prices are listed in US Dollars. Silverback Therapeutics employs 76 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Silverback Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – SBTX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Silverback Therapeutics stock price (NASDAQ: SBTX)Use our graph to track the performance of SBTX stocks over time.
Silverback Therapeutics shares at a glance
|Latest market close||$8.65|
|52-week range||$8.88 - $63.41|
|50-day moving average||$12.04|
|200-day moving average||$25.92|
|Wall St. target price||$45.40|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.23|
Buy Silverback Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Silverback Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Silverback Therapeutics price performance over time
|1 week (2021-10-21)||-6.89%|
|1 month (2021-09-28)||-19.98%|
|3 months (2021-07-28)||-71.61%|
|6 months (2021-04-28)||-75.09%|
|1 year (2020-10-24)||N/A|
|2 years (2019-10-24)||N/A|
|3 years (2018-10-24)||N/A|
|5 years (2016-10-24)||N/A|
Silverback Therapeutics financials
|Gross profit TTM||$0|
|Return on assets TTM||-10.03%|
|Return on equity TTM||-17.47%|
|Market capitalisation||$322.3 million|
TTM: trailing 12 months
Shorting Silverback Therapeutics shares
There are currently 4.0 million Silverback Therapeutics shares held short by investors – that's known as Silverback Therapeutics's "short interest". This figure is 9.9% up from 3.7 million last month.
There are a few different ways that this level of interest in shorting Silverback Therapeutics shares can be evaluated.
Silverback Therapeutics's "short interest ratio" (SIR)
Silverback Therapeutics's "short interest ratio" (SIR) is the quantity of Silverback Therapeutics shares currently shorted divided by the average quantity of Silverback Therapeutics shares traded daily (recently around 674294.639866). Silverback Therapeutics's SIR currently stands at 5.97. In other words for every 100,000 Silverback Therapeutics shares traded daily on the market, roughly 5970 shares are currently held short.
To gain some more context, you can compare Silverback Therapeutics's short interest ratio against those of similar companies.
However Silverback Therapeutics's short interest can also be evaluated against the total number of Silverback Therapeutics shares, or, against the total number of tradable Silverback Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Silverback Therapeutics's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Silverback Therapeutics shares in existence, roughly 110 shares are currently held short) or 0.228% of the tradable shares (for every 100,000 tradable Silverback Therapeutics shares, roughly 228 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Silverback Therapeutics.
Find out more about how you can short Silverback Therapeutics stock.
Silverback Therapeutics share dividends
We're not expecting Silverback Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
- Gilead Sciences (GILD.US) (4.15% forward annual dividend yield)
- GlaxoSmithKline (GSK.US) (2.02% forward annual dividend yield)
- HCA Healthcare (HCA.US) (0.37% forward annual dividend yield)
Silverback Therapeutics overview
Silverback Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Silverback Therapeutics in the news
Hohimer Wealth Management, Llc Buys Global Payments Inc, Las Vegas Sands Corp, Sanofi SA, Sells Alibaba Group Holding, Smith & Wesson Brands Inc, Bristol-Myers Squibb Co
H.C. Wainwright to hold a virtual conference
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Frequently asked questionsWhat percentage of Silverback Therapeutics is owned by insiders or institutions?
Currently 8.336% of Silverback Therapeutics shares are held by insiders and 86.269% by institutions. How many people work for Silverback Therapeutics?
Latest data suggests 76 work at Silverback Therapeutics. When does the fiscal year end for Silverback Therapeutics?
Silverback Therapeutics's fiscal year ends in December. Where is Silverback Therapeutics based?
Silverback Therapeutics's address is: 500 Fairview Avenue North, Seattle, WA, United States, 98109 What is Silverback Therapeutics's ISIN number?
Silverback Therapeutics's international securities identification number is: US82835W1080
More guides on Finder
How and where to buy NFTs
Read our comprehensive look at NFTs, including what they are, how to invest and the risks attached with buying them.
How to buy Trump Media and Technology Group (TMTG) stock when it goes public
Everything we know about the Trump Media and Technology Group IPO, plus information on how to buy in.
How to buy Valkyrie Bitcoin Strategy ETF (BTF)
Steps to owning and managing Valkyrie Bitcoin Strategy ETF units.
Today’s top US stocks: KE Holdings ADRs (BEKE ↑9.1%), Futu Holdings ADRs (FUTU ↑7.8%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Oct. 21, 2021
How to buy ProShares Bitcoin Strategy ETF (BITO)
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
How to buy The Real Good Food Company (RGF) stock when it goes public
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
How to buy Lulu’s Fashion Lounge Holdings (LVLU) stock when it goes public
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
How to buy Allarity Therapeutics (ALLR) stock when it goes public
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
How to buy Jupiter Neurosciences (JUNS) stock when it goes public
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
How to buy Mainz Biomed (MYNZ) stock when it goes public
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Ask an Expert